Synsight

High-Content Screening for AI-based Drug Discovery

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Évry, France
  • Currency EUR
  • Founded December 2013
  • Employees 6
  • Incorporation Type Other
  • Website synsight.net

Company Summary

SYNSIGHT’s platform encompasses Artificial Intelligence, Molecular Modeling and High-Content Screening to rationalize and accelerate drug discovery projects of its partners.
SYNSIGHT's business model involves developing R&D collaborations and licensing agreements with biotech companies and pharmaceutical companies. SYNSIGHT would be in charge of the discovery of new innovative drug candidates from a new target from the partner.

Team

  • Cyril Bauvais
    CEO

    PhD Chemoinformatics,
    management of academic and industrial programs, national and international research programs

  • Guillaume Bollot
    CSO

    PhD Computational Chemistry,
    Studies related to enzyme design, enzyme catalysis, drug design and artificial macromolecules, national and international research programs.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free